These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19277124)

  • 1. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.
    Mai PL; Chatterjee N; Hartge P; Tucker M; Brody L; Struewing JP; Wacholder S
    PLoS One; 2009; 4(3):e4812. PubMed ID: 19277124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
    Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
    J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
    Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
    Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
    N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
    J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
    Agalliu I; Gern R; Leanza S; Burk RD
    Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
    Dagan E
    Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
    Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME
    J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
    Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
    J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
    Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB
    J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.